INTRODUCTION AND OBJECTIVES:
To create a userfriendly, personalized decision support tool that can display the likelihood of readmission after radical cystectomy, as well as recommendations for optimal follow-up based on published data.
METHODS: We developed the "REACT: Readmission Elimination App for Cystectomy Treatment" using Apple's Xcode. This tool uses delay-time analysis models to determine the optimal timing of office visits and phone calls in order to maximize the probability of detecting radical cystectomy patients susceptible to readmission. We calibrated and validated the tool using radical cystectomy patient data from the [2009] [2010] RESULTS: Our decision support tool generates a forecasted probability of readmission as well as suggested follow-up frequencies. Sample screenshots from the tool are presented in the Figure. After inputting the date of hospital discharge and other patient characteristics, the app tracks the status of the patient, suggests an optimal follow-up strategy, provides patients with the ability to contact their provider by phone, and tracks future appointments.
CONCLUSIONS: We integrated a delay-time analysis methodology into a software tool that can run on personal computers, iPads and iPhones to improve follow-up of patients after radical cystectomy. This software generates real-time predictions of the likelihood of readmission and indicates when future follow-up should be performed, so as to identify clinical deterioration in a timely manner. Through further customization and pilot testing, this decision support tool will enable personalized follow-up to help prevent hospital readmission after radical cystectomy. . 197, No. 4S, Supplement, Friday, May 12, 2017 (data set-1:previously reported in IHC of DSC2), which included 39 cases of pure UC and 18 cases of UC with SD. Next, we confirmed the result in the other data set of 77 cases of muscle invasive bladder cancer treated with cystectomy from 2006 to 2015 (data set-2). RESULTS: In dataset-1, the positivity of UPK3, CK5/6 and DSC2 in pure UC was 46%, 21% and 0%, while the positivity in UC with SD was 0%, 83% and 100%, respectively. CK5/6 expression correlated with DSC2 expression, and UPK3 expression was mutually exclusive of both CK5/6 and DSC2 expression. In addition, the positivity of UPK3 and CK5/6 in papillary tumors was 43% and 14%, respectively, and in flat and non-papillary tumors was 28% and 49%, respectively. In normal urothelium, UPK3 expression was observed only in umbrella cells, while CK5/6 expression was detected only in the basal layer. The intermediate layer showed no staining with either marker. UPK3 positive cases had the most favorable cancer specific survival (CSS at 5 years; 83%), while CK5/6 positive cases had the worst prognosis (55%), and cases negative for both markers had an intermediate prognosis (68%). In dataset-2, the expression of UPK3 and CK5/6 in papillary UC was 57% and 4%, respectively, while expression in flat and non-papillary UC was 11% and 39%, respectively. CSS at 5 years was 95% in UPK3 positive, 49% in CK5/6 positive and 59% in marker-negative cases.
Source of
CONCLUSIONS: While genomic subtyping of UC requires clustering of large datasets derived from an entire cohort of patients, our simple IHC with two markers of luminal and basal differentiation is capable of stratifying prognosis on an individual patient basis. IHC classification of UC lends itself to easy adoption in routine clinical practice. 0 urgent suspected cancer 0 (USC) referrals suggested that asymptomatic microhematuria (AMH) need not be seen as USC. We hypothesized that declining referrals for AMH was safe, and would help to address our unacceptably long wait for the one-stop hematuria clinic (OSHC). We present the outcome of rejecting referrals for AMH entirely for one year, the first study of its kind to adopt this innovative approach.
METHODS: Hematuria referrals to a UK cancer center (catchment population >600K) were analyzed retrospectively prior to NG12 publication from July 14 to July 15 (cohort 1) and compared to prospective data following NG12 from July 15 to July 16 (cohort 2). After NG12, referrals for AMH were declined in writing. Bladder cancer was categorized as per the European Organisation for Research and Treatment of Cancer risk stratification.
RESULTS: Over the study period, 1963 patients were seen in a OSHC; 1105 prior to NG12 (cohort 1), and 858 after (cohort 2). In cohort 1, 686 had gross hematuria (GH), 159 had symptomatic microhematuria (SMH), and 260 had AMH. Cancers were diagnosed in 132 cohort 1 patients; 83% (110 patients) had urothelial malignancies, of which 107 (97%) presented with GH or SMH, and only 3 with AMH. Twenty-six patients (23%) were diagnosed with high-risk non-muscle invasive bladder cancer (HRNMIBC), 21 patients (19%) with muscle invasive bladder cancer (MIBC), and 4 (4%) with upper tract TCC (UTTCC). In cohort 2, 137 cancers were diagnosed, of which 114 (83%) were urothelial malignancies. These included 26 HRNMIBCs (23%), 24 MIBCs (21%), 3 metastatic bladder cancers (3%), and 7 UTTCCs (6%). Onehundred and fifty-three referrals for AMH were rejected in writing during cohort 2. By excluding patients with AMH from cohort 1, only 3 low-risk non-muscle invasive bladder cancers would have remained undetected after implementing NG12 (in addition to 2 small renal tumors).
Furthermore, after NG12, the average time from referral to first appointment fell from 35 days in July 15, to 17 days in July 16 (up to 50% reduction).
CONCLUSIONS: Prior to NICE guideline NG12 implementation, no significant cancers were detected in patients referred with AMH in our study. After NG12, and rejecting referrals with AMH entirely, patients with bladder cancer were seen and treated earlier. While such a novel approach to AMH may attract criticism, this study outlines for the first time, that declining to accept such referrals in a state-funded healthcare system is an effective approach for rationalization of resources. (BCa) is one of the top ten most common cancers in the world. However, very few studies have reported on health disparities involving advanced BCa. The objective of this study was to identify disparities in treatment and survival for patients with metastatic bladder cancer.
METHODS: Patients with metastatic BCa diagnosed between 1991 and 2014 were identified through the California Cancer Registry. Included in the analysis were age at diagnosis, sex, race/ethnicity, areabased socioeconomic status (SES), first course of treatment, and survival time. Predictors of treatment were identified using logistic regression, and cause-specific survival was analyzed using Cox regression.
RESULTS: A total of 3,073 cases of metastatic BCa were identified. Among these cases, 67.39% were male, and 32.61% were female. The race distribution was 74.78% non-Hispanic (NH) white, 6.25% NH black, 12.46% Hispanic and 5.96% NH Asian/Pacific Islander (Asian/PI). Among all patients presenting with metastatic bladder cancer, 45.6% received chemotherapy. Of those receiving chemotherapy, 42% underwent additional local treatment (radical cystectomy or radiotherapy). Patients over age 65, female patients and those residing in all but the wealthiest census tracts were less likely to receive chemotherapy with or without local treatment. NH black patients also were slightly less likely to be treated. Patients diagnosed between 2003 and 2014 were 32% more likely to receive chemotherapy than those diagnosed between 1991 and 2002 (p<.001). Overall and causespecific survival for the entire cohort was 11.1% and 14.5%, respectively. A smaller proportion of NH black patients survived two years after diagnosis (6.5% versus 14.4% NH white, 18.3% Hispanic, and 15.4% Asian/PI). After adjustment for other factors, patients aged 80 and older were more likely to die from bladder cancer (HR¼1.2, 95% CI¼1.0-1.3) as were black patients (HR¼1.2, 95% CI¼1.0-1.5). Patients residing in poorer census tracts were slightly more likely to die of bladder cancer although results were not statistically significant. Patients who received no chemotherapy had more than twice the risk of death. There was no evidence that overall survival improved in the most recent time period.
CONCLUSIONS: Non-Hispanic blacks and patients who were not treated with chemotherapy experienced poorer survival than other groups. There had been no improvement in this heath disparity or in overall survival over the last two decades.
